●Despite the high initial rates of response to anti-BCMA CAR-T cell therapy in myeloma, those responses are frequently short-lived.●Exhausted CD4+ CAR-T cells, identified by single cell assays in the patients’ blood and marrow, is linked to early relapse.●Myeloid cells in the myeloma niche blunt CD4+ CAR-T killing via TGFβ.